Phase I study of pre-operative combination therapy with Mogamulizumab (anti-CCR4) and Nivolumab (anti-PD-1) against solid cancer patients

Trial Profile

Phase I study of pre-operative combination therapy with Mogamulizumab (anti-CCR4) and Nivolumab (anti-PD-1) against solid cancer patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
  • Indications Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 25 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top